

## FOREWORD

Prostate cancer is a life-altering diagnosis, not just for patients, but for their loved ones as well. Once, prostate cancer was most frequently diagnosed in men in their 60s and 70s; with increasing use of imaging modalities and PSA testing, the incidence is on the rise, and we are now seeing men in their 40s with the disease. This poses a challenge for clinical management depending on the stage of the disease—from watchful waiting or active surveillance to aggressive treatment with the risk of therapeutic nihilism. While localized prostate cancer diagnosed at early stages is curable in most cases, the prognosis for metastatic disease is poor. Most patients with advanced disease will develop resistance to therapy and we need to understand more about the disease and develop efficacious therapeutic strategies for prostate cancer.

This book enhances our understanding of this disease in many ways: identifying who we need to diagnose, those most at risk based on their genetic profile, and also where diagnosis and treatment may not be in an individual's best interests. It looks into the future where the diagnostic pathway merges with the treatment with theranostics and reflects on lessons we can learn from the past. This book is a comprehensive and current account, covering the whole sphere of prostate cancer.

The editors, Simon Bott and Keng Ng, are to be congratulated for amassing such stellar contributors who together have produced a book that is easy to read but also highly informative. I enjoyed reading each chapter and I would encourage all those involved in the world of prostate cancer to do the same.

Professor Richard Hindley, MSc, FRCS (Urol)  
Visiting Professor, University of Winchester, England  
Consultant Urologist, Basingstoke and North Hampshire Hospital, England  
May 2021

Doi: <https://doi.org/10.36255/exonpublications.prostatecancer.foreword.2021>

